




Distressed asset investing by Katalysen Ventures

An update for Katalysen
Ventures' shareholders

Includes case study
from acquisition of:



Important: Note that the following is a short introduction to Katalysen Venture's portfolio company Venture Targeter. This document has been compiled for the purpose of updating shareholders in Katalysen Ventures on the progress being made by Venture Targeter. This document is not an invitation to participate in an investment in any shape or form.

- **Founded by Katalysen Ventures:** Venture Targeter AB (“VT”) was founded by Katalysen Ventures (“Katalysen”) to identify, structure, and execute special situation investments alongside co-investors and sector experts.
- **Focused on Special Situations:** VT specializes in special situation investments, focusing on distressed assets and in restructuring and turning around companies to realize untapped value.
- **Katalysen’s Role:** As a 33% shareholder in VT, Katalysen primarily provides the experience and expertise needed for VT to identify, structure, and execute these special situation investments.
- **Inaugural Investment Completed:** As communicated to markets on 22/11/2023, Venture Targeter has concluded its inaugural special situation investment into biotech company QuTEM (formerly Vironova BioAnalytics).
- **Result:** Once valued at SEK 2+ BN, VT invested into QuTEM in a winning offer for the bankruptcy estate. Post-transaction 3rd party analysts value QuTEM at SEK 230, more than 15X above the valuation at VT’s entry.
- **Looking Forward:** As a strategic complement to Katalysen Ventures, Venture Targeter is aiming to execute 2-3 transactions of a similar nature during 2024, for the benefit of the shareholders in Katalysen Ventures.



1 Source distressed assets with 2-3X potential on day 1 and minimum 10X potential over 3 years.




2. Acquisition, stabilization and turnaround together with investors and partners, each investment structured as a Special Purpose Vehicle.



3. Exit within 3 years, cash distributed to Venture Targeter stakeholders.

- **Acquisition Context:** Vironova BioAnalytics, previously a high-potential TEM (Transmission Electron Microscopy) service provider, faced financial challenges following shareholder disputes, leading to bankruptcy.
- **Investment Opportunity:** Recognizing a valuable opportunity, a consortium led by Quatre Lab, including VT, secured the acquisition from the bankruptcy estate.
- **Previous Valuation vs. Acquisition Cost:** Once valued at SEK 2+ BN and confirmed through Hitachi Hitech's investment, the company was acquired for a fraction of its peak value.
- **Strategic Significance:** The low acquisition cost presents a unique opportunity for rapid and significant value appreciation.





- 1 SEK 2 BN valuation in deal with Hitachi
- 2 VT's point of entry
- 3 QuTEM SEK 0.22 BN valuation two months post acquisition
- 4 Forecasted SEK 0.9 BN valuation 3 years post acquisition

• Key Contributions:


- VT was instrumental in securing vital IP rights, and the retention of key talent and staff, both cornerstones for the future growth of Vironova BioAnalytics (post-acquisition rebranded to QuTEM).
- Contributed in securing investments to carry company to positive cash flows.
- Successfully negotiated with the bankruptcy administrator, showcasing a solid plan for Vironova BioAnalytics' revival, which was critical in winning the deal against other bidders.

Third Party Valuation of QuTEM (formerly Vironova BioAnalytics)

Method	Used	Weight	Valuation [SEK]	Notes
Cost-based valuation	Yes	30%	31,868,420.30	Includes all reported costs
Asset-based valuation	Yes	30%	66,326,000.00	Includes all identified tangible and intangible assets
Earnings-based average valuation	Yes	30%	651,422,339.28	Valuation using 17 weighted models, with a 3 year timeframe
Internal benchmark-based valuation	Yes	-	-	Weighted average of 1 benchmarks available
External benchmark-based valuation	No	-	-	Not included in valuation
Qualitative-based valuation	Yes	10%	45,971,902.38	Based on 6.37 quality grade across 1 model
Return-based valuation	No	-	-	Not included in valuation
Weighted final valuation			227,982,218.11	

- The "Valuation Report - QuTEM" by Apollonian Research Advisory provides a comprehensive valuation of QuTEM, analyzing the company's value through multiple methods.
- QuTEM is projected to be cash flow positive by Q1 or Q2 2024 and expected to reach a value exceeding SEK 400 M by the end of 2024.

- This opportunity was identified, structured, and executed by Katalysen Ventures through Venture Targeter.
- Katalysen Ventures' 33% stake in VT translates to significant indirect ownership in QuTEM.
- With QuTEM's SEK 230 M valuation today, Katalysen's share is estimated to be worth around SEK 23 M as of late 2023 (as communicated to markets on 06/12/2023).
- Should QuTEM reach its forecasted value of SEK 900 M at the end of 2027, Katalysen's share would be worth an estimated SEK 90 M. An exit from QuTEM is deemed likely within the next 3 years, through a trade sale or IPO.
- VT is viewed as a strategic complement to Katalysen Ventures, and VT expects to execute 2-3 similar transactions during 2024 for the benefit of Katalysen Ventures' shareholders.



**For more information,
contact Katalysen Ventures**

Tobias Mathiasen
Chief Operating Officer
tm@katalysen.com

www.katalysen.com

**VENTURE
TARGETER**